Anzeige
Mehr »
Login
Donnerstag, 23.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Micro Cap & Branchenriese: Heute rein? - Partnerschaft entfacht Übernahmefantasien!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
552 Leser
Artikel bewerten:
(2)

Alkame Holdings, Inc.: Alkame Holdings Signs Troov and Begins Product Development

Finanznachrichten News

LAS VEGAS, NV / ACCESSWIRE / December 1, 2021 / Alkame Holdings, Inc. (OTC PINK:ALKM), is pleased to announce that it has signed an agreement to begin product development of Troov.

Troov will feature high performance formulas, launching first with an energy drink designed specifically for working out. The product is 12oz and will be available in three flavors. It is packed with health and wellness benefits including clean energy with no crash, made from real fruits and vegetables, with no synthetic ingredients, additives or added sugars.

Troov is 100% ethically sourced and plant-based with clinical dosages of hero performance ingredient and geared towards improving endurance and performance to support exercise efficiency and reduce muscular fatigue. Troov will target the growing number of recreational and competitive athletes with its benefits in reducing recovery times and increasing cardio output.

Troov' s ingredients are combined with ALKM's patented technology that alters the structure of water, producing a combination of characteristics that are unprecedented in the beverage industry. The ALKM technology includes an oxygenated alkaline water formulated with antioxidants and electrolytes for effective hydration.

"We are very excited to be moving so quickly with West Coast Copacker," stated Maxx Holdrieth, CEO of Troov. Maxx added, "Working with a well know water treatment technology for the base of our product really fits perfectly with our target audience and we very much look forward to a long and fruitful relationship together. We can't wait to bring this new generation of plant-based performance beverages to the market."

About West Coast Co Packer, Inc.

West Coast Co Packer, Inc., is a wholly owned subsidiary of Alkame Holdings, Inc. and is a specialty liquid and single-serve manufacturer, co-packer, private labeler, and contract manufacturer, and is expected to immediately complement and seamlessly integrate with Alkame's other subsidiaries including Bell Food and Beverage, Inc. Bell Food and Beverage, Inc. is a specialty natural, organic liquid-based hot and cold fill food & beverage manufacturer in glass and PET bottles and jars. To learn more about West Coast Copacker visit www.westcoastcopacker.com.

About Alkame Holdings, Inc.

Alkame Holdings, Inc. is a publicly traded health and wellness technology holding company, with a focus on patentable, innovative, and eco-friendly consumer products. The Company's wholly owned subsidiaries manufacture products with enhanced water utilizing a proprietary technology to create products with several unique properties. The organization is diligently building a strong foundation through the launch and acquisition of appropriate business assets, and by pursuing multiple applications by placement into several emerging business sectors, such as consumer bottled water and RTD products, household pet products, horticulture and agriculture applications, hand sanitizers, and many other various water-based treatment solutions to both new and existing business platforms.

For more information, visit www.alkameholdingsinc.com.

Alkame Holdings, Inc. Investor Relations
Website: www.alkameholdingsinc.com
Email: info@alkameholdingsinc.com

Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that Alkame will achieve significant sales, the failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

SOURCE: Alkame Holdings, Inc.



View source version on accesswire.com:
https://www.accesswire.com/675476/Alkame-Holdings-Signs-Troov-and-Begins-Product-Development

© 2021 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.